The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Identifying gut microbial signatures associated with B cells and tertiary lymphoid structures (TLS) in the tumor microenvironment (TME) in response to immune checkpoint blockade (ICB).
 
Elise F Nassif
No Relationships to Disclose
 
Manoj Chelvanambi
No Relationships to Disclose
 
Lili Chen
Employment - AstraZeneca (I)
Stock and Other Ownership Interests - AstraZeneca (I); Regencell Bioscience (I)
Honoraria - AstraZeneca (I)
 
Chia-Chin Wu
No Relationships to Disclose
 
Ashish Damania
No Relationships to Disclose
 
Emily Zhi-Yun Keung
No Relationships to Disclose
 
Russell G. Witt
No Relationships to Disclose
 
Michael White
No Relationships to Disclose
 
Nadim J. Ajami
Stock and Other Ownership Interests - Moderna Therapeutics
Research Funding - SNIPR BIOME
 
Matthew C. Wong
No Relationships to Disclose
 
Neeta Somaiah
Stock and Other Ownership Interests - JNJ (I); Pfizer (I)
Consulting or Advisory Role - AADi; Bayer; Blueprint Medicines; Boehringer Ingelheim; Deciphera; Epizyme
Research Funding - Ascentage Pharma; AstraZeneca/MedImmune (Inst); Daiichi Sankyo/Lilly; Deciphera; GlaxoSmithKline; Karyopharm Therapeutics
 
Boris Sepesi
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex
Speakers' Bureau - AstraZeneca
 
Sreyashi Basu
No Relationships to Disclose
 
James Patrick Allison
Stock and Other Ownership Interests - Achelois Oncology; Adaptive Biotechnologies; Apricity Health; BioAtla; BioNTech; Candel Therapeutics; Codiak Biosciences; Dragonfly Therapeutics; Earli; Enable Medicine; Hummingbird; ImaginAb; lava therapeutics; Lytix Biopharma; Marker Therapeutics; PBM Capital; Phenomic AI; Polaris; Time Bioventures; Trained Therapeutix Discovery; Two Bear Capital; Venn Biosciences Corporation
Honoraria - Achelois Oncology; Adaptive Biotechnologies; Apricity Health; BioAtla; BioNTech; Candel Therapeutics; Codiak Biosciences; Dragonfly Therapeutics; Earli; Enable Medicine; Hummingbird; ImaginAb; lava therapeutics; Lytix Biopharma; Marker Therapeutics; PBM Capital; Phenomic AI; Polaris; Time Bioventures; Trained Therapeutix Discovery; Two Bear Capital; Venn Biosciences Corporation
Consulting or Advisory Role - Achelois Oncology; Adaptive Biotechnologies; Apricity Health; BioAtla; BioNTech; Candel Therapeutics; Codiak Biosciences; Dragonfly Therapeutics; Earli; Enable Medicine; Hummingbird; ImaginAb; lava therapeutics; Lytix Biopharma; Marker Therapeutics; PBM Capital; Phenomic AI; Polaris; Time Bioventures; Trained Therapeutix Discovery; Two Bear Capital; Venn Biosciences Corporation
Patents, Royalties, Other Intellectual Property - Jounce Therapeutics; Merck
 
Padmanee Sharma
Stock and Other Ownership Interests - Achelois Oncology; Achelois Oncology (I); Adaptive Biotechnologies; Adaptive Biotechnologies (I); Affini-T Therapeutics; Affini-T Therapeutics (I); Apricity Health; Apricity Health (I); BioAtla; BioAtla (I); BioNTech; BioNTech (I); Candel Therapeutics; Candel Therapeutics (I); Catalio; Codiak Biosciences; Codiak Biosciences (I); Dragonfly Therapeutics; Dragonfly Therapeutics (I); Earli; Earli (I); Enable Medicine; Enable Medicine (I); Forty Seven; Forty Seven (I); Glympse Bio; Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Infinity Pharmaceuticals; Inimmune; InterVenn Biosciences; InterVenn Biosciences (I); Jounce Therapeutics; Jounce Therapeutics (I); JSL Health; Lava Therapeutics; Lava Therapeutics (I); Lytix Biopharma; Lytix Biopharma (I); Marker Therapeutics; Marker Therapeutics (I); Oncolytics; PBM Capital; PBM Capital (I); Phenomic AI; Phenomic AI (I); Polaris; Polaris (I); Sporos Bio; Time Bioventures; Trained Therapeutix Discovery; Trained Therapeutix Discovery (I); Two Bear Capital; Two Bear Capital (I)
Consulting or Advisory Role - Achelois Oncology; Achelois Oncology (I); Apricity Health; Apricity Health (I); BioAtla; BioAtla (I); Codiak Biosciences; Codiak Biosciences (I); Constellation Pharmaceuticals; Dragonfly Therapeutics; Dragonfly Therapeutics (I); Forty Seven; Forty Seven (I); Glympse Bio; Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Infinity Pharmaceuticals; Jounce Therapeutics; Jounce Therapeutics (I); Lava Therapeutics; Lava Therapeutics (I); Lytix Biopharma; Lytix Biopharma (I); Marker Therapeutics; Marker Therapeutics (I); Oncolytics; Polaris; Polaris (I)
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I)
 
Kevin McBride
No Relationships to Disclose
 
Wolf-Hervé Fridman
Stock and Other Ownership Interests - OSE Immunotherapeutics
Honoraria - GlaxoSmithKline
Consulting or Advisory Role - Adaptimmune; Anaveon; Catalym; Elsalys Biotech; Genenta Science; Novartis; Oxford BioTherapeutics; Parthenon Therapeutics
Patents, Royalties, Other Intellectual Property - HalioDx
 
Jennifer Ann Wargo
Stock and Other Ownership Interests - Micronoma
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Dava Oncology; Genentech; Gilead Sciences; GlaxoSmithKline; Illumina; Merck; Novartis; Society for Immunotherapy of Cancer
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Illumina; Merck; Novartis
Speakers' Bureau - Dava Oncology; Genentech; Illumina; Novartis; PER; Precision Health Economics; Precision Health Economics
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Patent submitted regarding the role of the microbiome in response to immune checkpoint blockade
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Dava Oncology; Genentech; GlaxoSmithKline; Illumina; Novartis
 
Tina Cascone
Honoraria - Bristol-Myers Squibb; Brystol-Myers Squibb; Medscape; Roche; Society for Immunotherapy of Cancer
Consulting or Advisory Role - Arrowhead Pharmaceuticals; AstraZeneca; Bristol Myers Squibb; EMD Serono; Genentech; MedImmune; Merck
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); MedImmune (Inst)
Travel, Accommodations, Expenses - Parker Institute for Cancer Immunotherapy
 
Christina Lynn Roland
Research Funding - Bristol-Myers Squibb